HR Execs on the Move

Kriya Therapeutics

www.kriyatherapeutics.com

 
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Sherry Clough
Vice President Supply Chain Profile
Michele Stone
Senior Vice President Research and Development Profile
Nachi Gupta
Chief Of Staff Profile

Similar Companies

Lexaria Bioscience

Lexaria Bioscience Corp. has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending and granted in over 40 countries around the world and was granted its first patent in the USA in October, 2016. Lexaria`s technology provides increases of up to 10x in intestinal absorption rates; more rapid delivery to the bloodstream with effects often within 15-20 minutes; and important taste-masking benefits, for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

ProThera Biologics (Main)

ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Texcell NA

Texcell NA is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FOB Synthesis

FOB Synthesis is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.